Neumora Therapeutics to Host Virtual R&D Day on October 27

Rhea-AI Summary

Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, will host a virtual R&D Day on October 27, 2025, at 8:00 a.m. ET. The event will showcase the company's pipeline of seven programs targeting novel mechanisms for prevalent diseases.

Key presentations will feature NMRA-215, a brain-penetrant NLRP3 inhibitor for obesity treatment, NMRA-511 Phase 1b data for Alzheimer's agitation, the M4 franchise (NMRA-861 and NMRA-898), and navacaprant, a Phase 3 kappa opioid receptor antagonist.

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&D Day on Monday, October 27, 2025, at 8:00 a.m. ET. Neumora is advancing a robust pipeline of novel mechanisms of action that each have the potential to fundamentally change the treatment paradigm.

The R&D Day will highlight NMRA-215, a potential best-in-class, highly potent and brain-penetrant NLRP3 inhibitor, including preclinical results from diet-induced obesity (DIO) mouse models evaluating its potential to treat obesity. Additional sessions will focus on expectations for the upcoming Phase 1b topline data readout for NMRA-511, a vasopressin 1a receptor antagonist being evaluated for the treatment of agitation in Alzheimer's disease; Neumora’s M4 franchise, including NMRA-861 and NMRA-898; and navacaprant, a kappa opioid receptor antagonist that is currently in Phase 3 studies.

Webcast Information
The event will begin at 8:00 a.m. ET on Monday, October 27, 2025. Participants can register for the live webcast here. In addition, the live webcast of the event will be available on the events and presentations section of the Company’s website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Neumora
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients; the timing, progress and plans for its therapeutic development programs, including the timing of clinical trial initiation and data readouts and upcoming milestones and catalysts and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Other than statements of historical facts, all statements contained in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause the actual results to be materially different from the information expressed or implied by these forward-looking statements, including, among others: the risks related to the inherent uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals; risks related to the timely initiation and enrollment in our clinical trials; risks related to our reliance on third parties, including contract research organizations; risks related to serious or undesirable side effects of our therapeutic candidates; risks related to our ability to utilize and protect our intellectual property rights; and other matters that could affect sufficiency of capital resources to fund operations. For a detailed discussion of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Neumora’s business in general, please refer to the risk factors identified in the Company’s filings with the Securities and Exchange Commission (SEC), including but not limited to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 which was filed with the SEC on August 6, 2025. Forward-looking statements speak only as of the date hereof, and, except as required by law, Neumora undertakes no obligation to update or revise these forward-looking statements. Our results for the quarter ended June 30, 2025 are also not necessarily indicative of our operating results for any future periods.

Neumora Contact:
Helen Rubinstein
617-402-5700
Helen.Rubinstein@neumoratx.com

FAQ

When is Neumora Therapeutics (NMRA) hosting its R&D Day and how can investors access it?

Neumora will host its virtual R&D Day on October 27, 2025, at 8:00 a.m. ET. Investors can access the live webcast through registration and the company's website at www.neumoratx.com.

What pipeline programs will Neumora (NMRA) discuss during its R&D Day?

Neumora will discuss NMRA-215 for obesity treatment, NMRA-511 Phase 1b data for Alzheimer's agitation, the M4 franchise (NMRA-861 and NMRA-898), and navacaprant in Phase 3 studies.

What is NMRA-215 and what is its potential application?

NMRA-215 is a highly potent and brain-penetrant NLRP3 inhibitor being evaluated as a potential best-in-class treatment for obesity, with preclinical results from diet-induced obesity mouse models to be presented.

What clinical stage is Neumora's (NMRA) navacaprant program currently in?

Navacaprant, a kappa opioid receptor antagonist, is currently in Phase 3 studies.

How long will the Neumora (NMRA) R&D Day webcast replay be available?

The webcast replay will be archived for up to 30 days following the completion of the event.